Agios Pharmaceuticals | Passivo Circulante



Current Liabilities Alterar Data
AbbVie USD 38.75B 4.31B 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
Amgen USD 23.1B 2.79B 2024-12
Arrowhead Research USD 93.76M 9.41M 2024-12
Astellas Pharma JPY 1.15T 59.2B 2024-12
AstraZeneca USD 27.87B 1.94B 2024-12
Bayer EUR 28.95B 3.9B 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Daiichi Sankyo JPY 712.36B 68.42B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
Exelixis USD 403.77M 9.42M 2025-01
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 21.7B 238M 2024-12
Incyte USD 1.64B 140.2M 2024-12
Ionis Pharmaceuticals USD 309.32M 4.75M 2024-12
Merck USD 28.42B 1.17B 2024-12
Moderna USD 2.21B 5M 2024-12
Novartis USD 28.69B 560M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 43B 216M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Roche Holding CHF 27.02B 424M 2024-12
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Agios Pharmaceuticals Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2025.